ratios in pulmonary tissues to avoid resistance development in bacteria.
-- Activity in biofilms: studies in an established in vitro biofilm system
showed that levofloxacin potency was least affected compared to
tobramycin or aztreonam.
-- Activity in anaerobic environments: antimicrobial susceptibility in
more than 100 P. aeruginosa isolates from CF patients was compared
between aerobic and anaerobic testing conditions. The geometric mean of
the MIC in levofloxacin treated isolates increased less than two fold
under anaerobic conditions, whereas tobramycin, amikacin and aztreonam
treated isolates increased 4-7 fold under anaerobic conditions. This
implies that MP-376 may retain its potency in anaerobic environments in
the lung more effectively compared to other classes of antibiotics.
-- Activity in CF sputum: Studies of antibiotic activity in CF sputum
showed that levofloxacin retained its full antibacterial activity
against P. aeruginosa whereas tobramycin activity was decreased by 1-2
logs in the presence of CF sputum, consistent with previous studies.
-- Convenient dosing regimen: In an in vivo model of a chronic lung
infection due to P. aeruginosa, MP-376 showed comparable antibacterial
activity when administered once or twice per day. In contrast, current
treatment options must be administered at least 2-3 times per day for
In addition to these preclinical studies, Mpex is also presenting data
at the NACFC meeting indicating that MP-376 has anti-inflammatory activity
that is independent of its antibacterial effect. This was demonstrated in
both in vitro and in vivo models and includes effects on both IL-6 and
IL-8, cytokines which have both been implicated in destructive inflammatory
processes in CF lungs. Th
|SOURCE Mpex Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved